143 related articles for article (PubMed ID: 32284737)
41. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
Li X; Wu Y; Liu A; Tang X
Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141
[TBL] [Abstract][Full Text] [Related]
42. HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
Chen L; Hu N; Wang C; Zhao H
Arch Biochem Biophys; 2020 Feb; 680():108244. PubMed ID: 31904363
[TBL] [Abstract][Full Text] [Related]
43. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.
Wu M; Soler DR; Abba MC; Nunez MI; Baer R; Hatzis C; Llombart-Cussac A; Llombart-Bosch A; Aldaz CM
Mol Cancer Res; 2007 Dec; 5(12):1285-95. PubMed ID: 18171986
[TBL] [Abstract][Full Text] [Related]
44. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer.
Xue X; Yang YA; Zhang A; Fong KW; Kim J; Song B; Li S; Zhao JC; Yu J
Oncogene; 2016 May; 35(21):2746-55. PubMed ID: 26364613
[TBL] [Abstract][Full Text] [Related]
45. Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205.
Zhang HY; Liang F; Zhang JW; Wang F; Wang L; Kang XG
Cancer Chemother Pharmacol; 2017 Feb; 79(2):327-337. PubMed ID: 28063065
[TBL] [Abstract][Full Text] [Related]
46. Identification and Validation of HOTAIRM1 as a Novel Biomarker for Oral Squamous Cell Carcinoma.
Yu Y; Niu J; Zhang X; Wang X; Song H; Liu Y; Jiao X; Chen F
Front Bioeng Biotechnol; 2021; 9():798584. PubMed ID: 35087800
[TBL] [Abstract][Full Text] [Related]
47. Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.
Cutrupi S; Reineri S; Panetto A; Grosso E; Caizzi L; Ricci L; Friard O; Agati S; Scatolini M; Chiorino G; Lykkesfeldt AE; De Bortoli M
Oncogene; 2012 Oct; 31(40):4353-61. PubMed ID: 22249258
[TBL] [Abstract][Full Text] [Related]
48. Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells.
Khanal P; Yun HJ; Lim SC; Ahn SG; Yoon HE; Kang KW; Hong R; Choi HS
Oncogene; 2012 Aug; 31(34):3845-56. PubMed ID: 22158035
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of β-Catenin to Overcome Endocrine Resistance in Tamoxifen-Resistant Breast Cancer Cell Line.
Won HS; Lee KM; Oh JE; Nam EM; Lee KE
PLoS One; 2016; 11(5):e0155983. PubMed ID: 27196739
[TBL] [Abstract][Full Text] [Related]
50. HDAC2 and HDAC5 Up-Regulations Modulate Survivin and miR-125a-5p Expressions and Promote Hormone Therapy Resistance in Estrogen Receptor Positive Breast Cancer Cells.
Huang WT; Tsai YH; Chen SH; Kuo CW; Kuo YL; Lee KT; Chen WC; Wu PC; Chuang CY; Cheng SM; Lin CH; Leung EY; Chang YC; Cheung CHA
Front Pharmacol; 2017; 8():902. PubMed ID: 29326587
[TBL] [Abstract][Full Text] [Related]
51. AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells.
Campbell PS; Mavingire N; Khan S; Rowland LK; Wooten JV; Opoku-Agyeman A; Guevara A; Soto U; Cavalli F; Loaiza-Pérez AI; Nagaraj G; Denham LJ; Adeoye O; Jenkins BD; Davis MB; Schiff R; Brantley EJ
J Cell Physiol; 2018 Jan; 234(1):108-121. PubMed ID: 30076704
[TBL] [Abstract][Full Text] [Related]
52. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
Ojo D; Lin X; Wu Y; Cockburn J; Bane A; Tang D
Cancer Lett; 2018 Jul; 426():4-13. PubMed ID: 29626519
[TBL] [Abstract][Full Text] [Related]
53. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer.
Zheng L; Li X; Meng X; Chou J; Hu J; Zhang F; Zhang Z; Xing Y; Liu Y; Xi T
Mol Cell Endocrinol; 2016 May; 427():133-42. PubMed ID: 26980484
[TBL] [Abstract][Full Text] [Related]
54. FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer.
Pellegrino M; Rizza P; Donà A; Nigro A; Ricci E; Fiorillo M; Perrotta I; Lanzino M; Giordano C; Bonofiglio D; Bruno R; Sotgia F; Lisanti MP; Sisci D; Morelli C
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31769419
[No Abstract] [Full Text] [Related]
55. HOTAIRM1 as a potential biomarker for diagnosis of colorectal cancer functions the role in the tumour suppressor.
Wan L; Kong J; Tang J; Wu Y; Xu E; Lai M; Zhang H
J Cell Mol Med; 2016 Nov; 20(11):2036-2044. PubMed ID: 27307307
[TBL] [Abstract][Full Text] [Related]
56. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ
Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929
[TBL] [Abstract][Full Text] [Related]
57. Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer.
Han X; Li Q; Liu C; Wang C; Li Y
J Cell Biochem; 2019 Aug; 120(8):12966-12976. PubMed ID: 31001849
[TBL] [Abstract][Full Text] [Related]
58. Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/β-catenin Pathway.
Fu Y; Wang Z; Luo C; Wang Y; Wang Y; Zhong X; Zheng H
Transl Oncol; 2020 Feb; 13(2):423-440. PubMed ID: 31911277
[TBL] [Abstract][Full Text] [Related]
59. Prolyl isomerase PIN1 negatively regulates SGK1 stability to mediate tamoxifen resistance in breast cancer cells.
Jo A; Yun HJ; Kim JY; Lim SC; Choi HJ; Kang BS; Choi BY; Choi HS
Anticancer Res; 2015 Feb; 35(2):785-94. PubMed ID: 25667458
[TBL] [Abstract][Full Text] [Related]
60. The lncRNA-HOXA-AS2/EZH2/LSD1 oncogene complex promotes cell proliferation in pancreatic cancer.
Lian Y; Li Z; Fan Y; Huang Q; Chen J; Liu W; Xiao C; Xu H
Am J Transl Res; 2017; 9(12):5496-5506. PubMed ID: 29312501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
